Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Personalized targeted therapy in advanced non-small cell lung cancer
C. Patrick
Department of Medicine
Cancer Institute, Experimental Therapeutics
Penn State Cancer Institute
Division of Hematology and Oncology
Department of Molecular and Precision Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
46
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Personalized targeted therapy in advanced non-small cell lung cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Tumor
33%
Cell Survival
33%
Aberrations
33%
Tumor Heterogeneity
33%
Tumor Cells
33%
Oncogene
33%
Cetuximab
33%
Receptor Tyrosine Kinase
33%
Resistance Mechanisms
33%
Genetic Abnormalities
33%
Tumor Resistance
33%
Receptor Overexpression
33%
Erlotinib
33%
Gefitinib
33%
Combination of Therapies
33%
Cellular Heterogeneity
33%
Cell Maintenance
33%
Actionable Target
33%
Rational Therapy
33%
Crizotinib
33%
EGFR mutation
33%
Non-oncogene Addiction
33%
Human Kinome
33%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Targeted Therapy
100%
Treatment of Non-Small Cell Lung Cancer
66%
Neoplasm
33%
Tumour Heterogeneity
33%
Tumor Cell
33%
Cetuximab
33%
Epidermal Growth Factor Receptor
33%
Protein Tyrosine Kinase
33%
Tumor Resistance
33%
Oncogene
33%
Erlotinib
33%
Gefitinib
33%
Rational Emotive Behavior Therapy
33%
Crizotinib
33%
Biochemistry, Genetics and Molecular Biology
Oncogene
100%
Genetics
50%
Receptor Tyrosine Kinase
50%
Epidermal Growth Factor Receptor
50%
Gefitinib
50%
Erlotinib
50%
Cetuximab
50%
Kinome
50%
Crizotinib
50%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Neoplasm
60%
Protein Tyrosine Kinase
20%
Cetuximab
20%
Epidermal Growth Factor Receptor
20%
Erlotinib
20%
Gefitinib
20%
Tumor Resistance
20%
Crizotinib
20%
Oncogene Addiction
20%